Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

This study is testing a drug called sacituzumab govitecan in people with salivary gland cancers that have come back or spread and cannot be cured with surgery or radiation. It is an antibody-drug combination that targets a protein found on cancer cells. **You may be eligible if...** - You are 18 years old or older - You have a confirmed salivary gland cancer diagnosis that has returned or spread - Surgery or radiation to cure the cancer is no longer an option - Your cancer is measurable on imaging scans - Your general health is good (ECOG 0 or 1) - Your blood counts and kidney function meet minimum thresholds **You may NOT be eligible if...** - You have received a stem cell transplant in the past - You have uncontrolled infections - You are pregnant or breastfeeding - You have had certain prior treatments that overlap with this drug's mechanism Talk to your doctor to see if this trial is right for you.